Bio Association Hosts 'BioPlus-Interphex Korea 2022'

[Asia Economy Reporter Chunhee Lee] The Korea Bio Association announced on the 1st that it will hold the comprehensive bio convention "BioPlus-Interphex Korea 2022 (BIX 2022, Bioplus-Interphex Korea 2022)" for three days from the 3rd to the 5th of next month at COEX in Gangnam-gu, Seoul, inviting experts from various fields around the world in the bio and pharmaceutical sectors, together with Reed Exhibitions Korea.

Marking its 8th edition this year, the theme of BIX is "Summer in BIX," conveying the message to enjoy this summer with the bio and pharmaceutical industry convention. The event will feature conferences with renowned domestic and international figures, exhibitions and partnering programs covering all areas of bio, and corporate presentations.

The conference consists of keynote sessions and general sessions, held at the Grand Ballroom on the 1st floor and conference rooms on the 3rd floor of COEX. The keynote sessions bring together prominent figures in the bio industry. On the 3rd, under the theme "Drawing the Present and Future of the Korean Bio Industry in 2022," Hwang Mansoon, CEO of Korea Investment Partners, Lee Jungkyu, CEO of Bridge Biotherapeutics, and Choi Yoonhee, Senior Research Fellow at the Korea Institute for Industrial Economics & Trade (KIEF), will discuss key issues and future directions of the Korean bio industry. On the 5th, Virginijus Siksnys from Vilnius University in Lithuania, a world-renowned authority in biochemical gene research, will deliver a lecture titled "The Future of Gene Editing Technology."

The general sessions, consisting of 19 topics, cover various fields encompassed by bio. These include ▲How far has AI-driven new drug development come? ▲Valuation of bio companies ▲Bio cold chain logistics ▲Global new drug development: target protein decomposition and target protein upstream regulators ▲Impact of bio industry and ESG ▲Biomimetic technology, crossing the boundaries between non-clinical and clinical ▲Contract development and manufacturing organization (CDMO) business expansion strategies ▲Cross-border technology cooperation and technology export (case studies) ▲Bio convergence: from IT powerhouse to BT powerhouse ▲The infinite expansion of exosomes ▲Technology leakage due to talent drain? Technology security examined through the US Trade Secrets Protection Act! ▲Digital healthcare and the future insurance market ▲Clinical status of Alzheimer's treatment drugs ▲The future of gene scissors technology ▲Domestic and overseas listing strategies ▲Post-pandemic global clinical trials ▲Bio industry dive by domestic conglomerates ▲Preventive medicine through virtual clinical trials ▲Bio industry patent strategies. Additionally, luncheon seminars and 14 corporate sessions sponsored by leading domestic and international companies such as Cytiva, Sartorius, and Thermo Fisher will be held.

The exhibition themed on the K-Bio value chain will be organized on a scale of about 200 companies and 300 booths from home and abroad. The main categories include ▲Digital healthcare ▲Laboratory equipment and analysis ▲Manufacturing and facilities ▲Packaging ▲Logistics ▲Biotechnology ▲Raw materials (pharmaceuticals, food, cosmetics) ▲Services ▲Hospitals, universities, and public institutions. Especially, special exhibitions will be held this year on key topics in the bio and pharmaceutical industry such as ▲Contract manufacturing (CMO) and CDMO ▲Digital healthcare ▲Cold chain logistics ▲Bio materials, parts, and equipment.

Furthermore, an Open Innovation Stage to check the latest technologies of startup ventures and partnering programs to secure new business pipelines will be provided. Through partnering, attendees can meet over 200 participating companies including Pfizer, AstraZeneca, Samsung Bioepis, Samsung Biologics, Celltrion, Hanmi Pharmaceutical, and GC Cell.

BIX 2022 is currently open for pre-registration, and participation tickets can be purchased on the BIX website. Members of the Korea Bio Association are eligible for registration discounts.

This content was produced with the assistance of AI translation services.